
Takeda has announced it is abandoning the development of a vaccine in Japan that was in Phase II clinical trials.TAK-361S, …

Rajeev Venkayya is the president of the global vaccine business unit at Takeda Pharmaceuticals. He has served as special assistant …
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation

